{"gene":"ZNF224","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":2005,"finding":"ZNF224 binds in vivo to the distal promoter of the aldolase A gene and represses its transcription; this repression requires the 45-amino acid KRAB A domain and its interaction with the KAP-1 co-repressor, and also requires histone deacetylases (demonstrated by TSA sensitivity).","method":"Chromatin immunoprecipitation (ChIP), transient transfection/reporter assays, co-transfection with HDAC inhibitor trichostatin A, KRAB domain mutagenesis","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, reporter assay, co-transfection, inhibitor treatment, domain deletion) in a single focused study; replicated in subsequent work","pmids":["16150558"],"is_preprint":false},{"year":2009,"finding":"ZNF224 physically associates with the arginine methyltransferase PRMT5; PRMT5 is recruited to the L-type aldolase A promoter as part of the ZNF224 repressor complex, leading to symmetric dimethylation of arginine 3 of histone H4. RNAi knockdown of PRMT5 de-represses aldolase A transcription. The ZNF224–PRMT5 repressor complex occupies the promoter in a cell-cycle-dependent manner.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference, histone methylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP plus ChIP plus RNAi functional rescue, multiple orthogonal methods in one focused study","pmids":["19741270"],"is_preprint":false},{"year":2009,"finding":"ZNF224 binds a 26-bp silencer element (-595/-569) in the mitochondrial citrate carrier (CIC) promoter and represses CIC transcription; overexpression of ZNF224 decreases CIC reporter and endogenous transcript/protein, while ZNF224 knockdown activates CIC transcription.","method":"DNA affinity purification/protein identification, reporter (luciferase) assays, ZNF224 overexpression and siRNA knockdown, RT-PCR and Western blot for CIC","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNA affinity purification for identification plus gain/loss-of-function reporter experiments, single lab","pmids":["19505435"],"is_preprint":false},{"year":2010,"finding":"ZNF224 interacts with DEPDC1 (cancer-testis antigen) in bladder cancer cells, as shown by co-immunoprecipitation and colocalization. Disruption of the DEPDC1–ZNF224 complex with a cell-permeable peptide de-represses A20 transcription (an NF-κB inhibitor), triggering apoptosis in vitro and in vivo.","method":"Co-immunoprecipitation, immunocytochemistry/colocalization, cell-permeable peptide interference, luciferase/transcriptional assays, in vitro and xenograft apoptosis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus colocalization plus peptide-based functional rescue plus in vivo validation; multiple orthogonal methods","pmids":["20587513"],"is_preprint":false},{"year":2010,"finding":"ZNF224 (nuclear isoform) physically interacts with the WT1(−KTS) isoform in the nucleus, acting as a co-activator that enhances WT1-mediated transcriptional activation (e.g., of the vitamin D receptor promoter). ZNF255 (cytoplasmic/nucleolar isoform) interacts with WT1(+KTS) in a different subcellular compartment and is involved in RNA processing rather than transcription.","method":"Co-immunoprecipitation, subcellular fractionation/immunofluorescence, reporter (luciferase) transcriptional assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus compartment-specific localization plus functional reporter assay, single lab","pmids":["20591825"],"is_preprint":false},{"year":2007,"finding":"ZNF224 is homogeneously distributed in the nucleus, whereas its isoform ZNF255 (alternatively spliced from the same gene) localizes to subnuclear structures (nucleoli) and also to the cytoplasm; ZNF224 represses aldolase A NRE more efficiently than ZNF255, correlating with their distinct subcellular distributions.","method":"Northern blot, PCR, transient transfection with GFP-tagged proteins (immunofluorescence), ChIP","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct imaging of tagged proteins plus ChIP plus reporter assay, single lab","pmids":["17900823"],"is_preprint":false},{"year":2013,"finding":"In CML K562 cells, ZNF224 acts as a co-activator of WT1 on proapoptotic gene promoters while suppressing WT1-mediated transactivation of antiapoptotic genes; cytarabine (ara-C) induces ZNF224 expression, and this induction enhances the apoptotic response to ara-C.","method":"Reporter (luciferase) assays, co-immunoprecipitation, ChIP, siRNA knockdown, apoptosis assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus reporter assay plus functional apoptosis readout, single lab","pmids":["23362234"],"is_preprint":false},{"year":2015,"finding":"BCR-ABL oncogene signaling downregulates ZNF224 gene expression in CML; WT1 (whose expression is positively driven by BCR-ABL) transcriptionally represses the ZNF224 promoter, providing a pathway by which BCR-ABL suppresses apoptosis through ZNF224 repression.","method":"RT-PCR and Western blot in BCR-ABL+ cell lines and primary CML samples, reporter assays for ZNF224 promoter, imatinib/TKI treatment experiments","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay for promoter repression plus cell line and primary patient sample expression analysis plus drug rescue, single lab","pmids":["26320177"],"is_preprint":false},{"year":2015,"finding":"ZNF224 is recruited by WT1 to the IRF8 promoter and counteracts WT1-mediated repression of IRF8 transcription; ZNF224 knockdown suppresses both basal and cytarabine-induced IRF8 expression in K562 cells.","method":"Co-immunoprecipitation (nuclear), ChIP, shRNA knockdown, luciferase reporter assays","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus reporter assay plus shRNA functional validation, single lab","pmids":["26563595"],"is_preprint":false},{"year":2016,"finding":"ZNF224 binds a consensus 5'-CAGC-3' DNA motif (identified by ChIP-seq) and transcriptionally activates miR-663a by binding its promoter; miR-663a in turn binds the 3' UTR of p53 and p21 to reduce their expression, thereby promoting cell survival and apoptosis resistance.","method":"ChIP-sequencing, ELISA, surface plasmon resonance (SPR), qPCR, luciferase reporter assay, miR-663a antagonist rescue experiments","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq for DNA binding plus SPR for binding affinity plus reporter assay plus miRNA antagonist rescue; multiple orthogonal methods, single lab","pmids":["27105517"],"is_preprint":false},{"year":2017,"finding":"ZNF224 is a transcriptional repressor of c-Myc in CML cells; imatinib and the JAK2 inhibitor AG490 induce ZNF224 expression, which then represses c-MYC transcription, leading to apoptosis. This identifies the ZNF224/c-Myc axis as a determinant of imatinib responsiveness.","method":"Reporter (luciferase) assays for c-Myc promoter, ZNF224 overexpression/knockdown, RT-PCR and Western blot, drug treatment experiments (imatinib, AG490), apoptosis assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay plus gain/loss-of-function plus drug treatment, single lab","pmids":["29423056"],"is_preprint":false},{"year":2017,"finding":"MED28 physically interacts with ZNF224 via the KRAB domain of ZNF224 and the MED domain of MED28, in the nucleus; MED28 overexpression stabilizes ZNF224 protein by inhibiting its camptothecin (CPT)-induced degradation, resulting in increased colony formation of MCF-7 breast cancer cells.","method":"Co-immunoprecipitation, surface plasmon resonance (SPR), bimolecular fluorescence complementation (BiFC), domain mapping, colony formation assay","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus SPR plus BiFC plus domain-specific interaction mapping, single lab","pmids":["29435049"],"is_preprint":false},{"year":2018,"finding":"ZNF224 acts as a transcriptional repressor of AXL (receptor tyrosine kinase) in CML cells; ZNF224 overexpression suppresses AXL expression and partly restores imatinib sensitivity in imatinib-resistant CML cells.","method":"Reporter assays (AXL promoter), ChIP, ZNF224 overexpression/knockdown, Western blot, drug sensitivity assays","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter plus ChIP plus functional drug-resistance rescue, single lab","pmids":["30176265"],"is_preprint":false},{"year":2021,"finding":"ZNF224 expression is induced by TGF-β in melanoma cells and mediates TGF-β pro-oncogenic signaling; ZNF224 potentiates TGF-β/Smad-driven transcription of EMT target genes and positively modulates expression of TGF-β itself and its receptors TβR1 and TβR2, establishing a positive regulatory loop that promotes EMT and invasiveness.","method":"ZNF224 overexpression and knockdown, TGF-β stimulation, RT-PCR/Western blot for EMT markers and TGF-β pathway components, cell invasion/proliferation assays, reporter assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — gain/loss-of-function with multiple functional readouts (EMT gene expression, invasion, proliferation) plus reporter assay, single lab","pmids":["34181020"],"is_preprint":false},{"year":2022,"finding":"ZNF224 knockdown reduces NF-κB pathway activity in CLL cells, demonstrating that ZNF224 promotes CLL cell survival through NF-κB pathway modulation; ZNF224 silencing raises both spontaneous and drug-induced apoptosis and inhibits proliferation in primary CLL cells.","method":"RNA interference (ZNF224 knockdown), NF-κB reporter/activity assay, apoptosis assays, proliferation assays in primary CLL patient PBMCs","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — RNAi with multiple functional readouts (NF-κB activity, apoptosis, proliferation) in primary patient cells, single lab","pmids":["36425656"],"is_preprint":false},{"year":2025,"finding":"In melanoma cells, ZNF224 overexpression transcriptionally upregulates p21(CIP1/WAF1) in a p53-dependent manner and enhances AKT-triggered cytosolic retention of p21, inhibiting apoptosis and promoting cell proliferation; this reveals a mechanism by which ZNF224 co-opts p21's oncogenic function downstream of p53 and AKT signaling.","method":"ZNF224 overexpression/knockdown, p21 promoter reporter assays, p53 dependency experiments, AKT pathway inhibition, subcellular fractionation, apoptosis and proliferation assays, transcriptomic data analysis","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay plus fractionation plus multiple functional readouts, single lab, recently published","pmids":["40321146"],"is_preprint":false}],"current_model":"ZNF224 is a KRAB-domain-containing Krüppel-like zinc finger transcription factor that represses target genes (aldolase A, CIC, c-Myc, AXL) by recruiting the co-repressor KAP1, the arginine methyltransferase PRMT5 (which symmetrically dimethylates histone H4 Arg3), and histone deacetylases to target promoters; its transcriptional activity is context-dependent, as it can also act as a co-activator/co-repressor modulator when partnering with WT1 isoforms on apoptotic gene promoters, enhance TGF-β/Smad-driven EMT signaling in melanoma, upregulate miR-663a to suppress p53/p21, stabilize p21 via AKT-driven cytosolic retention, and promote NF-κB survival signaling in leukemia — with its molecular outcome determined by cell type, binding partners (DEPDC1, MED28, WT1), and post-translational stability regulated by MED28."},"narrative":{"mechanistic_narrative":"ZNF224 is a KRAB-domain Krüppel-like zinc finger protein that functions as a sequence-specific transcription factor, binding a 5'-CAGC-3' consensus motif and acting predominantly as a repressor while adopting context-dependent activating or modulatory roles depending on cell type and partner [PMID:16150558, PMID:27105517]. Its core repressive mechanism relies on the KRAB A domain, which recruits the co-repressor KAP-1 and histone deacetylase activity to silence target promoters such as aldolase A [PMID:16150558]. ZNF224 also assembles a repressor complex with the arginine methyltransferase PRMT5, directing symmetric dimethylation of histone H4 arginine 3 at target promoters in a cell-cycle-dependent manner [PMID:19741270]; documented direct repression targets additionally include the mitochondrial citrate carrier CIC [PMID:19505435]. Beyond autonomous repression, ZNF224 acts as a co-regulator of WT1, enhancing WT1-driven activation of proapoptotic genes while counteracting WT1-mediated repression of others such as IRF8 [PMID:23362234, PMID:26563595]. In chronic myeloid leukemia ZNF224 is a tumor-suppressive node repressing c-Myc and AXL, and its expression is suppressed by BCR-ABL/WT1 signaling but restored by kinase inhibitors to promote apoptosis [PMID:26320177, PMID:29423056, PMID:30176265]. In other contexts ZNF224 supports survival and oncogenic phenotypes: it activates miR-663a to lower p53/p21 [PMID:27105517], promotes NF-κB-dependent survival in CLL [PMID:36425656], potentiates TGF-β/Smad-driven EMT in melanoma [PMID:34181020], and drives AKT-dependent cytosolic retention of p21 [PMID:40321146]. Its activity and stability are further shaped by partner binding, including DEPDC1, which sequesters ZNF224 to repress the NF-κB inhibitor A20 [PMID:20587513], and MED28, which binds the KRAB domain and protects ZNF224 from degradation [PMID:29435049].","teleology":[{"year":2005,"claim":"Established ZNF224 as a bona fide KRAB-zinc finger repressor by showing it occupies a target promoter in vivo and silences it through the canonical KRAB-A/KAP-1/HDAC axis.","evidence":"ChIP, reporter assays, KRAB domain mutagenesis, and HDAC inhibitor (TSA) treatment on the aldolase A promoter","pmids":["16150558"],"confidence":"High","gaps":["Did not define the full genomic target repertoire","Recruitment of specific HDAC enzymes not identified"]},{"year":2007,"claim":"Showed that alternative splicing generates the ZNF255 isoform with distinct subnuclear/cytoplasmic localization and weaker repressive capacity, linking subcellular distribution to function.","evidence":"Northern blot, GFP-tagged protein imaging, and ChIP comparing ZNF224 and ZNF255","pmids":["17900823"],"confidence":"Medium","gaps":["Functional role of cytoplasmic/nucleolar ZNF255 undefined","Single lab, no endogenous protein detection"]},{"year":2009,"claim":"Defined the enzymatic effector arm of ZNF224 repression by identifying PRMT5 as a complex partner that deposits the repressive H4R3 symmetric dimethyl mark in a cell-cycle-dependent manner.","evidence":"Reciprocal Co-IP, ChIP, PRMT5 RNAi de-repression, and histone methylation assay at the aldolase A promoter","pmids":["19741270"],"confidence":"High","gaps":["Whether PRMT5 recruitment generalizes beyond aldolase A unknown","Order of KAP-1 vs PRMT5 recruitment not resolved"]},{"year":2009,"claim":"Extended the repressive target set by mapping a discrete silencer element bound by ZNF224 in the CIC promoter and showing bidirectional control of CIC expression.","evidence":"DNA affinity purification, luciferase reporters, and ZNF224 overexpression/siRNA with RT-PCR and Western blot","pmids":["19505435"],"confidence":"Medium","gaps":["Direct in vivo promoter occupancy by ChIP not shown","Co-repressor requirement at CIC not tested"]},{"year":2010,"claim":"Revealed that ZNF224 is not a constitutive repressor but a partner-dependent co-regulator, acting as a WT1(−KTS) co-activator, recasting it as a context-switchable transcription factor.","evidence":"Co-IP, subcellular fractionation/immunofluorescence, and reporter assays with WT1 isoforms","pmids":["20591825"],"confidence":"Medium","gaps":["Structural basis of the activating vs repressive switch unknown","Single lab"]},{"year":2010,"claim":"Demonstrated a non-promoter sequestration mechanism whereby DEPDC1 binding restrains ZNF224 from repressing the NF-κB inhibitor A20, linking ZNF224 partner availability to survival signaling.","evidence":"Reciprocal Co-IP, colocalization, cell-permeable peptide disruption, and in vitro/xenograft apoptosis assays in bladder cancer","pmids":["20587513"],"confidence":"High","gaps":["Direct ZNF224 binding to the A20 promoter not mapped","Generality beyond bladder cancer untested"]},{"year":2013,"claim":"Showed ZNF224 differentially co-regulates WT1 targets in leukemia—activating proapoptotic and suppressing antiapoptotic genes—and that chemotherapy induces ZNF224 to enhance apoptosis.","evidence":"Reporter assays, Co-IP, ChIP, siRNA, and apoptosis assays with cytarabine in K562 cells","pmids":["23362234"],"confidence":"Medium","gaps":["Determinant of activating vs repressive outcome on individual WT1 targets unresolved","Single lab"]},{"year":2015,"claim":"Mapped a regulatory feedback whereby BCR-ABL, via WT1, transcriptionally represses ZNF224, establishing ZNF224 silencing as a route by which the oncogene blunts apoptosis.","evidence":"Promoter reporter assays, expression analysis in BCR-ABL+ lines and primary CML, and TKI treatment","pmids":["26320177"],"confidence":"Medium","gaps":["Direct WT1 occupancy of the ZNF224 promoter in vivo not shown","Single lab"]},{"year":2015,"claim":"Identified IRF8 as a target where ZNF224 counteracts WT1-mediated repression, reinforcing its role as a WT1 co-regulator in leukemia differentiation/apoptosis.","evidence":"Nuclear Co-IP, ChIP, shRNA knockdown, and reporter assays in K562 cells","pmids":["26563595"],"confidence":"Medium","gaps":["Mechanism by which ZNF224 overrides WT1 repression unclear","Single lab"]},{"year":2016,"claim":"Defined the ZNF224 DNA-binding consensus (5'-CAGC-3') genome-wide and uncovered an activating, pro-survival arm via miR-663a induction that lowers p53 and p21.","evidence":"ChIP-seq, SPR binding, reporter assays, and miR-663a antagonist rescue","pmids":["27105517"],"confidence":"High","gaps":["How the same factor activates miR-663a yet represses other genes mechanistically unresolved","Cofactors driving activation not identified"]},{"year":2017,"claim":"Established ZNF224 as a tumor-suppressive repressor of c-Myc whose drug-induced expression promotes apoptosis, defining a ZNF224/c-Myc axis governing imatinib response.","evidence":"c-Myc promoter reporters, gain/loss-of-function, and imatinib/AG490 treatment with apoptosis assays in CML","pmids":["29423056"],"confidence":"Medium","gaps":["Direct c-Myc promoter occupancy and co-repressor use not fully detailed","Single lab"]},{"year":2017,"claim":"Showed MED28 binds the ZNF224 KRAB domain and stabilizes ZNF224 against degradation, identifying post-translational control of ZNF224 abundance as a regulatory layer.","evidence":"Reciprocal Co-IP, SPR, BiFC, domain mapping, and colony formation in MCF-7 cells","pmids":["29435049"],"confidence":"Medium","gaps":["Degradation pathway (E3 ligase, ubiquitination) not identified","Effect on ZNF224 transcriptional targets not assessed"]},{"year":2018,"claim":"Identified AXL as an additional ZNF224 repression target in CML, linking ZNF224 loss to imatinib resistance and its restoration to resensitization.","evidence":"AXL promoter reporters, ChIP, gain/loss-of-function, and drug sensitivity assays","pmids":["30176265"],"confidence":"Medium","gaps":["Co-repressor machinery at AXL not characterized","Single lab"]},{"year":2021,"claim":"Revealed an oncogenic role in melanoma where TGF-β-induced ZNF224 potentiates Smad-driven EMT transcription and feeds back to upregulate TGF-β and its receptors.","evidence":"Gain/loss-of-function, TGF-β stimulation, EMT marker analysis, invasion/proliferation, and reporter assays","pmids":["34181020"],"confidence":"Medium","gaps":["Direct ZNF224 targets within the EMT program not mapped","Single lab"]},{"year":2022,"claim":"Demonstrated ZNF224 promotes CLL survival through NF-κB pathway modulation, with knockdown raising apoptosis and reducing proliferation in primary patient cells.","evidence":"RNAi with NF-κB activity, apoptosis, and proliferation assays in primary CLL PBMCs","pmids":["36425656"],"confidence":"Medium","gaps":["Direct transcriptional targets connecting ZNF224 to NF-κB undefined","Single lab"]},{"year":2025,"claim":"Showed ZNF224 co-opts p21 oncogenically in melanoma by transcriptionally upregulating p21 in a p53-dependent manner and promoting AKT-driven cytosolic retention to block apoptosis.","evidence":"p21 promoter reporters, p53-dependency and AKT-inhibition experiments, subcellular fractionation, and apoptosis/proliferation assays","pmids":["40321146"],"confidence":"Medium","gaps":["Direct ZNF224 binding to the p21 promoter versus indirect effect not distinguished","Single lab"]},{"year":null,"claim":"A unifying mechanistic determinant of when ZNF224 acts as a KAP-1/PRMT5-dependent repressor versus a WT1/Smad co-activator across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of partner-dependent activity switching","Genome-wide direct targets in non-leukemic contexts uncharacterized","Post-translational code governing repression vs activation unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,9,10,12]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,5,11]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,9,10,12]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,6,14,15]}],"complexes":[],"partners":["KAP1","PRMT5","WT1","DEPDC1","MED28"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NZL3","full_name":"Zinc finger protein 224","aliases":["Bone marrow zinc finger 2","BMZF-2","Zinc finger protein 233","Zinc finger protein 255","Zinc finger protein 27","Zinc finger protein KOX22"],"length_aa":707,"mass_kda":82.3,"function":"May be involved in transcriptional regulation as a transcriptional repressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NZL3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF224","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZNF224","total_profiled":1310},"omim":[{"mim_id":"616888","title":"TRANSMEMBRANE PROTEIN 8B; TMEM8B","url":"https://www.omim.org/entry/616888"},{"mim_id":"607102","title":"WT1 TRANSCRIPTION FACTOR; WT1","url":"https://www.omim.org/entry/607102"},{"mim_id":"606956","title":"ZINC FINGER PROTEIN 256; ZNF256","url":"https://www.omim.org/entry/606956"},{"mim_id":"194555","title":"ZINC FINGER PROTEIN 224; ZNF224","url":"https://www.omim.org/entry/194555"},{"mim_id":"194554","title":"ZINC FINGER PROTEIN 45; ZNF45","url":"https://www.omim.org/entry/194554"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF224"},"hgnc":{"alias_symbol":["BMZF-2","KOX22"],"prev_symbol":["ZNF255","ZNF27"]},"alphafold":{"accession":"Q9NZL3","domains":[{"cath_id":"3.30.160.60","chopping":"261-312","consensus_level":"medium","plddt":84.3981,"start":261,"end":312},{"cath_id":"3.30.160.60","chopping":"317-428","consensus_level":"medium","plddt":88.2854,"start":317,"end":428},{"cath_id":"3.30.160.60","chopping":"457-535","consensus_level":"medium","plddt":86.9359,"start":457,"end":535},{"cath_id":"3.30.160.60","chopping":"539-620","consensus_level":"medium","plddt":83.28,"start":539,"end":620},{"cath_id":"1.10.1200","chopping":"11-43","consensus_level":"medium","plddt":66.587,"start":11,"end":43}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZL3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZL3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZL3-F1-predicted_aligned_error_v6.png","plddt_mean":70.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF224","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF224"},"sequence":{"accession":"Q9NZL3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NZL3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NZL3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZL3"}},"corpus_meta":[{"pmid":"20587513","id":"PMC_20587513","title":"Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20587513","citation_count":86,"is_preprint":false},{"pmid":"16150558","id":"PMC_16150558","title":"The Krüppel-like zinc-finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 co-repressor protein.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16150558","citation_count":33,"is_preprint":false},{"pmid":"27105517","id":"PMC_27105517","title":"ZNF224, Krüppel like zinc finger protein, induces cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-663a.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27105517","citation_count":31,"is_preprint":false},{"pmid":"19741270","id":"PMC_19741270","title":"The Kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19741270","citation_count":31,"is_preprint":false},{"pmid":"20591825","id":"PMC_20591825","title":"Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20591825","citation_count":26,"is_preprint":false},{"pmid":"19505435","id":"PMC_19505435","title":"Transcription of the mitochondrial citrate carrier gene: identification of a silencer and its binding protein ZNF224.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19505435","citation_count":24,"is_preprint":false},{"pmid":"23362234","id":"PMC_23362234","title":"Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23362234","citation_count":22,"is_preprint":false},{"pmid":"26320177","id":"PMC_26320177","title":"WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26320177","citation_count":19,"is_preprint":false},{"pmid":"34181020","id":"PMC_34181020","title":"ZNF224 is a mediator of TGF-β pro-oncogenic function in melanoma.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34181020","citation_count":16,"is_preprint":false},{"pmid":"29423056","id":"PMC_29423056","title":"Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29423056","citation_count":15,"is_preprint":false},{"pmid":"26563595","id":"PMC_26563595","title":"The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.","date":"2015","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26563595","citation_count":15,"is_preprint":false},{"pmid":"21187159","id":"PMC_21187159","title":"ZNF224: Structure and role of a multifunctional KRAB-ZFP protein.","date":"2010","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21187159","citation_count":14,"is_preprint":false},{"pmid":"28040726","id":"PMC_28040726","title":"Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28040726","citation_count":14,"is_preprint":false},{"pmid":"17900823","id":"PMC_17900823","title":"Differential expression and cellular localization of ZNF224 and ZNF255, two isoforms of the Krüppel-like zinc-finger protein family.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17900823","citation_count":14,"is_preprint":false},{"pmid":"28215224","id":"PMC_28215224","title":"The Complex Role of the ZNF224 Transcription Factor in Cancer.","date":"2016","source":"Advances in protein chemistry and structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/28215224","citation_count":12,"is_preprint":false},{"pmid":"30176265","id":"PMC_30176265","title":"ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells.","date":"2018","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/30176265","citation_count":12,"is_preprint":false},{"pmid":"29435049","id":"PMC_29435049","title":"MED28 increases the colony-forming ability of breast cancer cells by stabilizing the ZNF224 protein upon DNA damage.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29435049","citation_count":9,"is_preprint":false},{"pmid":"36425656","id":"PMC_36425656","title":"Biological relevance of ZNF224 expression in chronic lymphocytic leukemia and its implication IN NF-kB pathway regulation.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36425656","citation_count":7,"is_preprint":false},{"pmid":"34684876","id":"PMC_34684876","title":"ZNF224 Protein: Multifaceted Functions Based on Its Molecular Partners.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34684876","citation_count":6,"is_preprint":false},{"pmid":"40321146","id":"PMC_40321146","title":"ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma.","date":"2025","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/40321146","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10684,"output_tokens":4100,"usd":0.046776,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11970,"output_tokens":4761,"usd":0.089438,"stage2_stop_reason":"end_turn"},"total_usd":0.136214,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"ZNF224 binds in vivo to the distal promoter of the aldolase A gene and represses its transcription; this repression requires the 45-amino acid KRAB A domain and its interaction with the KAP-1 co-repressor, and also requires histone deacetylases (demonstrated by TSA sensitivity).\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), transient transfection/reporter assays, co-transfection with HDAC inhibitor trichostatin A, KRAB domain mutagenesis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, reporter assay, co-transfection, inhibitor treatment, domain deletion) in a single focused study; replicated in subsequent work\",\n      \"pmids\": [\"16150558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZNF224 physically associates with the arginine methyltransferase PRMT5; PRMT5 is recruited to the L-type aldolase A promoter as part of the ZNF224 repressor complex, leading to symmetric dimethylation of arginine 3 of histone H4. RNAi knockdown of PRMT5 de-represses aldolase A transcription. The ZNF224–PRMT5 repressor complex occupies the promoter in a cell-cycle-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference, histone methylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP plus ChIP plus RNAi functional rescue, multiple orthogonal methods in one focused study\",\n      \"pmids\": [\"19741270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZNF224 binds a 26-bp silencer element (-595/-569) in the mitochondrial citrate carrier (CIC) promoter and represses CIC transcription; overexpression of ZNF224 decreases CIC reporter and endogenous transcript/protein, while ZNF224 knockdown activates CIC transcription.\",\n      \"method\": \"DNA affinity purification/protein identification, reporter (luciferase) assays, ZNF224 overexpression and siRNA knockdown, RT-PCR and Western blot for CIC\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNA affinity purification for identification plus gain/loss-of-function reporter experiments, single lab\",\n      \"pmids\": [\"19505435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF224 interacts with DEPDC1 (cancer-testis antigen) in bladder cancer cells, as shown by co-immunoprecipitation and colocalization. Disruption of the DEPDC1–ZNF224 complex with a cell-permeable peptide de-represses A20 transcription (an NF-κB inhibitor), triggering apoptosis in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, immunocytochemistry/colocalization, cell-permeable peptide interference, luciferase/transcriptional assays, in vitro and xenograft apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus colocalization plus peptide-based functional rescue plus in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"20587513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF224 (nuclear isoform) physically interacts with the WT1(−KTS) isoform in the nucleus, acting as a co-activator that enhances WT1-mediated transcriptional activation (e.g., of the vitamin D receptor promoter). ZNF255 (cytoplasmic/nucleolar isoform) interacts with WT1(+KTS) in a different subcellular compartment and is involved in RNA processing rather than transcription.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation/immunofluorescence, reporter (luciferase) transcriptional assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus compartment-specific localization plus functional reporter assay, single lab\",\n      \"pmids\": [\"20591825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZNF224 is homogeneously distributed in the nucleus, whereas its isoform ZNF255 (alternatively spliced from the same gene) localizes to subnuclear structures (nucleoli) and also to the cytoplasm; ZNF224 represses aldolase A NRE more efficiently than ZNF255, correlating with their distinct subcellular distributions.\",\n      \"method\": \"Northern blot, PCR, transient transfection with GFP-tagged proteins (immunofluorescence), ChIP\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct imaging of tagged proteins plus ChIP plus reporter assay, single lab\",\n      \"pmids\": [\"17900823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In CML K562 cells, ZNF224 acts as a co-activator of WT1 on proapoptotic gene promoters while suppressing WT1-mediated transactivation of antiapoptotic genes; cytarabine (ara-C) induces ZNF224 expression, and this induction enhances the apoptotic response to ara-C.\",\n      \"method\": \"Reporter (luciferase) assays, co-immunoprecipitation, ChIP, siRNA knockdown, apoptosis assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus reporter assay plus functional apoptosis readout, single lab\",\n      \"pmids\": [\"23362234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BCR-ABL oncogene signaling downregulates ZNF224 gene expression in CML; WT1 (whose expression is positively driven by BCR-ABL) transcriptionally represses the ZNF224 promoter, providing a pathway by which BCR-ABL suppresses apoptosis through ZNF224 repression.\",\n      \"method\": \"RT-PCR and Western blot in BCR-ABL+ cell lines and primary CML samples, reporter assays for ZNF224 promoter, imatinib/TKI treatment experiments\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay for promoter repression plus cell line and primary patient sample expression analysis plus drug rescue, single lab\",\n      \"pmids\": [\"26320177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZNF224 is recruited by WT1 to the IRF8 promoter and counteracts WT1-mediated repression of IRF8 transcription; ZNF224 knockdown suppresses both basal and cytarabine-induced IRF8 expression in K562 cells.\",\n      \"method\": \"Co-immunoprecipitation (nuclear), ChIP, shRNA knockdown, luciferase reporter assays\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus reporter assay plus shRNA functional validation, single lab\",\n      \"pmids\": [\"26563595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF224 binds a consensus 5'-CAGC-3' DNA motif (identified by ChIP-seq) and transcriptionally activates miR-663a by binding its promoter; miR-663a in turn binds the 3' UTR of p53 and p21 to reduce their expression, thereby promoting cell survival and apoptosis resistance.\",\n      \"method\": \"ChIP-sequencing, ELISA, surface plasmon resonance (SPR), qPCR, luciferase reporter assay, miR-663a antagonist rescue experiments\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq for DNA binding plus SPR for binding affinity plus reporter assay plus miRNA antagonist rescue; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"27105517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZNF224 is a transcriptional repressor of c-Myc in CML cells; imatinib and the JAK2 inhibitor AG490 induce ZNF224 expression, which then represses c-MYC transcription, leading to apoptosis. This identifies the ZNF224/c-Myc axis as a determinant of imatinib responsiveness.\",\n      \"method\": \"Reporter (luciferase) assays for c-Myc promoter, ZNF224 overexpression/knockdown, RT-PCR and Western blot, drug treatment experiments (imatinib, AG490), apoptosis assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay plus gain/loss-of-function plus drug treatment, single lab\",\n      \"pmids\": [\"29423056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MED28 physically interacts with ZNF224 via the KRAB domain of ZNF224 and the MED domain of MED28, in the nucleus; MED28 overexpression stabilizes ZNF224 protein by inhibiting its camptothecin (CPT)-induced degradation, resulting in increased colony formation of MCF-7 breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, surface plasmon resonance (SPR), bimolecular fluorescence complementation (BiFC), domain mapping, colony formation assay\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus SPR plus BiFC plus domain-specific interaction mapping, single lab\",\n      \"pmids\": [\"29435049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF224 acts as a transcriptional repressor of AXL (receptor tyrosine kinase) in CML cells; ZNF224 overexpression suppresses AXL expression and partly restores imatinib sensitivity in imatinib-resistant CML cells.\",\n      \"method\": \"Reporter assays (AXL promoter), ChIP, ZNF224 overexpression/knockdown, Western blot, drug sensitivity assays\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter plus ChIP plus functional drug-resistance rescue, single lab\",\n      \"pmids\": [\"30176265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZNF224 expression is induced by TGF-β in melanoma cells and mediates TGF-β pro-oncogenic signaling; ZNF224 potentiates TGF-β/Smad-driven transcription of EMT target genes and positively modulates expression of TGF-β itself and its receptors TβR1 and TβR2, establishing a positive regulatory loop that promotes EMT and invasiveness.\",\n      \"method\": \"ZNF224 overexpression and knockdown, TGF-β stimulation, RT-PCR/Western blot for EMT markers and TGF-β pathway components, cell invasion/proliferation assays, reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — gain/loss-of-function with multiple functional readouts (EMT gene expression, invasion, proliferation) plus reporter assay, single lab\",\n      \"pmids\": [\"34181020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF224 knockdown reduces NF-κB pathway activity in CLL cells, demonstrating that ZNF224 promotes CLL cell survival through NF-κB pathway modulation; ZNF224 silencing raises both spontaneous and drug-induced apoptosis and inhibits proliferation in primary CLL cells.\",\n      \"method\": \"RNA interference (ZNF224 knockdown), NF-κB reporter/activity assay, apoptosis assays, proliferation assays in primary CLL patient PBMCs\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — RNAi with multiple functional readouts (NF-κB activity, apoptosis, proliferation) in primary patient cells, single lab\",\n      \"pmids\": [\"36425656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In melanoma cells, ZNF224 overexpression transcriptionally upregulates p21(CIP1/WAF1) in a p53-dependent manner and enhances AKT-triggered cytosolic retention of p21, inhibiting apoptosis and promoting cell proliferation; this reveals a mechanism by which ZNF224 co-opts p21's oncogenic function downstream of p53 and AKT signaling.\",\n      \"method\": \"ZNF224 overexpression/knockdown, p21 promoter reporter assays, p53 dependency experiments, AKT pathway inhibition, subcellular fractionation, apoptosis and proliferation assays, transcriptomic data analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay plus fractionation plus multiple functional readouts, single lab, recently published\",\n      \"pmids\": [\"40321146\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF224 is a KRAB-domain-containing Krüppel-like zinc finger transcription factor that represses target genes (aldolase A, CIC, c-Myc, AXL) by recruiting the co-repressor KAP1, the arginine methyltransferase PRMT5 (which symmetrically dimethylates histone H4 Arg3), and histone deacetylases to target promoters; its transcriptional activity is context-dependent, as it can also act as a co-activator/co-repressor modulator when partnering with WT1 isoforms on apoptotic gene promoters, enhance TGF-β/Smad-driven EMT signaling in melanoma, upregulate miR-663a to suppress p53/p21, stabilize p21 via AKT-driven cytosolic retention, and promote NF-κB survival signaling in leukemia — with its molecular outcome determined by cell type, binding partners (DEPDC1, MED28, WT1), and post-translational stability regulated by MED28.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF224 is a KRAB-domain Krüppel-like zinc finger protein that functions as a sequence-specific transcription factor, binding a 5'-CAGC-3' consensus motif and acting predominantly as a repressor while adopting context-dependent activating or modulatory roles depending on cell type and partner [#0, #9]. Its core repressive mechanism relies on the KRAB A domain, which recruits the co-repressor KAP-1 and histone deacetylase activity to silence target promoters such as aldolase A [#0]. ZNF224 also assembles a repressor complex with the arginine methyltransferase PRMT5, directing symmetric dimethylation of histone H4 arginine 3 at target promoters in a cell-cycle-dependent manner [#1]; documented direct repression targets additionally include the mitochondrial citrate carrier CIC [#2]. Beyond autonomous repression, ZNF224 acts as a co-regulator of WT1, enhancing WT1-driven activation of proapoptotic genes while counteracting WT1-mediated repression of others such as IRF8 [#6, #8]. In chronic myeloid leukemia ZNF224 is a tumor-suppressive node repressing c-Myc and AXL, and its expression is suppressed by BCR-ABL/WT1 signaling but restored by kinase inhibitors to promote apoptosis [#7, #10, #12]. In other contexts ZNF224 supports survival and oncogenic phenotypes: it activates miR-663a to lower p53/p21 [#9], promotes NF-κB-dependent survival in CLL [#14], potentiates TGF-β/Smad-driven EMT in melanoma [#13], and drives AKT-dependent cytosolic retention of p21 [#15]. Its activity and stability are further shaped by partner binding, including DEPDC1, which sequesters ZNF224 to repress the NF-κB inhibitor A20 [#3], and MED28, which binds the KRAB domain and protects ZNF224 from degradation [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established ZNF224 as a bona fide KRAB-zinc finger repressor by showing it occupies a target promoter in vivo and silences it through the canonical KRAB-A/KAP-1/HDAC axis.\",\n      \"evidence\": \"ChIP, reporter assays, KRAB domain mutagenesis, and HDAC inhibitor (TSA) treatment on the aldolase A promoter\",\n      \"pmids\": [\"16150558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full genomic target repertoire\", \"Recruitment of specific HDAC enzymes not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed that alternative splicing generates the ZNF255 isoform with distinct subnuclear/cytoplasmic localization and weaker repressive capacity, linking subcellular distribution to function.\",\n      \"evidence\": \"Northern blot, GFP-tagged protein imaging, and ChIP comparing ZNF224 and ZNF255\",\n      \"pmids\": [\"17900823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of cytoplasmic/nucleolar ZNF255 undefined\", \"Single lab, no endogenous protein detection\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the enzymatic effector arm of ZNF224 repression by identifying PRMT5 as a complex partner that deposits the repressive H4R3 symmetric dimethyl mark in a cell-cycle-dependent manner.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, PRMT5 RNAi de-repression, and histone methylation assay at the aldolase A promoter\",\n      \"pmids\": [\"19741270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRMT5 recruitment generalizes beyond aldolase A unknown\", \"Order of KAP-1 vs PRMT5 recruitment not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended the repressive target set by mapping a discrete silencer element bound by ZNF224 in the CIC promoter and showing bidirectional control of CIC expression.\",\n      \"evidence\": \"DNA affinity purification, luciferase reporters, and ZNF224 overexpression/siRNA with RT-PCR and Western blot\",\n      \"pmids\": [\"19505435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vivo promoter occupancy by ChIP not shown\", \"Co-repressor requirement at CIC not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed that ZNF224 is not a constitutive repressor but a partner-dependent co-regulator, acting as a WT1(−KTS) co-activator, recasting it as a context-switchable transcription factor.\",\n      \"evidence\": \"Co-IP, subcellular fractionation/immunofluorescence, and reporter assays with WT1 isoforms\",\n      \"pmids\": [\"20591825\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the activating vs repressive switch unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated a non-promoter sequestration mechanism whereby DEPDC1 binding restrains ZNF224 from repressing the NF-κB inhibitor A20, linking ZNF224 partner availability to survival signaling.\",\n      \"evidence\": \"Reciprocal Co-IP, colocalization, cell-permeable peptide disruption, and in vitro/xenograft apoptosis assays in bladder cancer\",\n      \"pmids\": [\"20587513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ZNF224 binding to the A20 promoter not mapped\", \"Generality beyond bladder cancer untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed ZNF224 differentially co-regulates WT1 targets in leukemia—activating proapoptotic and suppressing antiapoptotic genes—and that chemotherapy induces ZNF224 to enhance apoptosis.\",\n      \"evidence\": \"Reporter assays, Co-IP, ChIP, siRNA, and apoptosis assays with cytarabine in K562 cells\",\n      \"pmids\": [\"23362234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinant of activating vs repressive outcome on individual WT1 targets unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped a regulatory feedback whereby BCR-ABL, via WT1, transcriptionally represses ZNF224, establishing ZNF224 silencing as a route by which the oncogene blunts apoptosis.\",\n      \"evidence\": \"Promoter reporter assays, expression analysis in BCR-ABL+ lines and primary CML, and TKI treatment\",\n      \"pmids\": [\"26320177\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct WT1 occupancy of the ZNF224 promoter in vivo not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified IRF8 as a target where ZNF224 counteracts WT1-mediated repression, reinforcing its role as a WT1 co-regulator in leukemia differentiation/apoptosis.\",\n      \"evidence\": \"Nuclear Co-IP, ChIP, shRNA knockdown, and reporter assays in K562 cells\",\n      \"pmids\": [\"26563595\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ZNF224 overrides WT1 repression unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the ZNF224 DNA-binding consensus (5'-CAGC-3') genome-wide and uncovered an activating, pro-survival arm via miR-663a induction that lowers p53 and p21.\",\n      \"evidence\": \"ChIP-seq, SPR binding, reporter assays, and miR-663a antagonist rescue\",\n      \"pmids\": [\"27105517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same factor activates miR-663a yet represses other genes mechanistically unresolved\", \"Cofactors driving activation not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established ZNF224 as a tumor-suppressive repressor of c-Myc whose drug-induced expression promotes apoptosis, defining a ZNF224/c-Myc axis governing imatinib response.\",\n      \"evidence\": \"c-Myc promoter reporters, gain/loss-of-function, and imatinib/AG490 treatment with apoptosis assays in CML\",\n      \"pmids\": [\"29423056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct c-Myc promoter occupancy and co-repressor use not fully detailed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed MED28 binds the ZNF224 KRAB domain and stabilizes ZNF224 against degradation, identifying post-translational control of ZNF224 abundance as a regulatory layer.\",\n      \"evidence\": \"Reciprocal Co-IP, SPR, BiFC, domain mapping, and colony formation in MCF-7 cells\",\n      \"pmids\": [\"29435049\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Degradation pathway (E3 ligase, ubiquitination) not identified\", \"Effect on ZNF224 transcriptional targets not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified AXL as an additional ZNF224 repression target in CML, linking ZNF224 loss to imatinib resistance and its restoration to resensitization.\",\n      \"evidence\": \"AXL promoter reporters, ChIP, gain/loss-of-function, and drug sensitivity assays\",\n      \"pmids\": [\"30176265\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-repressor machinery at AXL not characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed an oncogenic role in melanoma where TGF-β-induced ZNF224 potentiates Smad-driven EMT transcription and feeds back to upregulate TGF-β and its receptors.\",\n      \"evidence\": \"Gain/loss-of-function, TGF-β stimulation, EMT marker analysis, invasion/proliferation, and reporter assays\",\n      \"pmids\": [\"34181020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ZNF224 targets within the EMT program not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated ZNF224 promotes CLL survival through NF-κB pathway modulation, with knockdown raising apoptosis and reducing proliferation in primary patient cells.\",\n      \"evidence\": \"RNAi with NF-κB activity, apoptosis, and proliferation assays in primary CLL PBMCs\",\n      \"pmids\": [\"36425656\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets connecting ZNF224 to NF-κB undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed ZNF224 co-opts p21 oncogenically in melanoma by transcriptionally upregulating p21 in a p53-dependent manner and promoting AKT-driven cytosolic retention to block apoptosis.\",\n      \"evidence\": \"p21 promoter reporters, p53-dependency and AKT-inhibition experiments, subcellular fractionation, and apoptosis/proliferation assays\",\n      \"pmids\": [\"40321146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ZNF224 binding to the p21 promoter versus indirect effect not distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying mechanistic determinant of when ZNF224 acts as a KAP-1/PRMT5-dependent repressor versus a WT1/Smad co-activator across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of partner-dependent activity switching\", \"Genome-wide direct targets in non-leukemic contexts uncharacterized\", \"Post-translational code governing repression vs activation unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 9, 10, 12]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 5, 11]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 9, 10, 12]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 6, 14, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"KAP1\", \"PRMT5\", \"WT1\", \"DEPDC1\", \"MED28\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}